Press Releases

  • VolitionRx Announces New Chief Financial Officer

  • VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif

  • VolitionRx Appoints Dr. Habib Skaff to Board of Directors

  • VolitionRx Announces First Published Data in Anticancer Research Journal

  • VolitionRx Extends Agreement With University Hospital Bonn to Include CE Mark Performance Evaluation

  • President and CEO of VolitionRx Issues Corporate Update

  • New VolitionRx Study Data Demonstrates NuQ(R) Assays' High Detection Rate of Prostate Cancer and the Ability to Distinguish Between Prostate and Colorectal Cancer

  • VolitionRx Completes $3 Million Private Placement

  • VolitionRx Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark

  • VolitionRx Presents at MicroCapClub Invitational

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus